Prevalência e fatores associados ao uso de medicamento indutor do sono entre mulheres assistidas na Atenção Primária à Saúde: estudo transversal em Vitória, Espírito Santo, 2014 / Prevalencia y factores asociados al uso de medicamentos inductores del sueño en mujeres atendidas en Atención Primaria de Salud: estudio transversal en Vitória, Espírito Santo, Brasil, 2014 / Prevalence and factors associated with the use of sleep-inducing medication among women receiving Primary Health Care: a cross-sectional study in Vitória, Espírito Santo, Brazil, 2014

Objetivo: Verificar a prevalência e fatores associados ao uso de medicamento indutor do sono entre mulheres assistidas na Atenção Primária à Saúde (APS), Vitória, ES, Brasil. Métodos: Estudo transversal com mulheres de 20-59 anos, realizado em 2014. Analisou-se a associação do uso de indutor do sono com fatores socioeconômicos e experiências de violência (regressão de Poisson). Resultados: Entre 991 participantes, 18,5% usavam medicamento indutor do sono e 45,9% usaram-no alguma vez na vida. Seu uso, atualmente e ao longo da vida, associou-se a idade, escolaridade e violências psicológica, física e sexual no último ano (p-valor<0,05). Menor renda familiar (RP=1,30; IC95% 1,03;1,64) e parceiro controlador (RP=1,35; IC95% 1,08;1,69) associaram-se ao uso atual, enquanto experiência de violência sexual na infância (RP=1,33; IC95% 1,13;1,56) associou-se ao uso alguma vez na vida. Conclusão: O uso de medicamento indutor do sono foi frequente entre usuárias da APS, associando-se a fatores socioeconômicos e experiências de violência.

Objetivo: Verificar la prevalencia y los factores asociados al uso de medicamentos inductores del sueño en mujeres en la Atención Primaria de Salud (APS) de Vitória, ES, Brasil. Métodos: Estudio transversal con mujeres de 20 a 59 años realizado en 2014. Se analizó la asociación del uso de inductores del sueño con factores socioeconómicos y violencia (regresión de Poisson). Resultados: Entre las 991 participantes, 18,5% usó medicamentos inductores y 45,9% los había usado en algún momento. El uso, actual y en la vida, de estos medicamentos se asoció con la edad, años de educación, violencia psicológica, física y sexual en el último año (p-valor<0,05). Ingresos familiares bajos (RP=1,30; IC95% 1,03;1,64) y pareja controladora (RP=1,35; IC95% 1,08;1,69) se asociaron con el uso actual, mientras que la experiencia de violencia en la infancia (RP=1,33; IC95% 1,13;1,56) se asoció con el uso alguna vez en la vida. Conclusión: El uso de inductores del sueño fue frecuente entre usuarias de la APS, asociado a factores socioeconómicos y violencia.

Objective: To verify prevalence and factors associated with the use of sleep-inducing medication among women receiving primary health care (PHC) in Vitória, ES, Brazil. Methods: This was a cross-sectional study conducted in 2014 with women aged 20-59. We analyzed association of sleep-inducing medication use with socioeconomic factors and experiences of violence (Poisson regression). Results: Out of 991 participants, 18.5% were using sleep-inducing medication and 45.9% had used it at some point in their lives. Current and lifetime use of these medications was associated with age, years of education, as well as psychological, physical and sexual violence in the last year (p-valor<0,05). Lower family income (PR=1.30; 95%CI 1.03;1.64) and controlling partner (PR=1.35; 95%CI 1.08;1.69) were associated with current use, while experience of sexual violence in childhood (PR=1.33; 95%CI 1.13;1.56) was associated with lifetime use. Conclusion: Use of sleep-inducing medication was frequent among PHC service users, and was associated with socioeconomic factors and experiences of violence.

Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial

Objective: To evaluate the safety and efficacy of a 5 mg sublingual dose of zolpidem, compared to a 10 mg oral dose, at bedtime and "as needed" following middle-of-the-night awakenings. Methods: Participants were randomized into an oral group (oral zolpidem 10 mg and sublingual placebo at bedtime and "as-needed") and a sublingual group (oral placebo and sublingual zolpidem 5 mg at bedtime and "as-needed"). Participants underwent medical evaluation, polysomnography, the psychomotor vigilance test, and completed questionnaires. Results: Of 85 patients, 67 met the criteria for insomnia (48±10 years; 79% women) and were randomized. Of these, 46 completed 92±5 days of treatment. Mild-to-moderate adverse events were reported by 25% of the participants, including headache, sleepiness, and dizziness. Both treatments decreased middle-of-the-night awakenings by an average of -3.1±2.3 days/week and increased total sleep time by 1.5 hours. Changes in sleep quality and insomnia severity scores were also favorable and comparable between groups: variation depended on continuation of treatment. Regarding PSG findings, sleep latency decreased more in the sublingual group than the oral group (-14±42 vs. 10±29 min; p = 0.03). The psychomotor vigilance test showed minor residual effects 30 minutes after awakening, which reversed after 2 hours. Conclusions: The safety and efficacy of both zolpidem formulations are comparable. The sublingual 5 mg dose induced sleep more rapidly. Clinical trial registration: NCT01896336